Y-mAbs Therapeutics’ (YMAB) Outperform Rating Reaffirmed at Wedbush

Y-mAbs Therapeutics (NASDAQ:YMAB)‘s stock had its “outperform” rating reiterated by equities researchers at Wedbush in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $23.00 price target on the stock. Wedbush’s target price would indicate a potential upside of 72.03% from the company’s previous close.

A number of other equities research analysts have also commented on the stock. BMO Capital Markets lowered their price target on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, August 13th. Morgan Stanley lowered their price target on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a report on Tuesday, August 13th. Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 price target on shares of Y-mAbs Therapeutics in a report on Monday. Canaccord Genuity Group reissued a “buy” rating and set a $26.00 price objective on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Finally, HC Wainwright reissued a “buy” rating and set a $22.00 price objective on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Y-mAbs Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $21.14.

Y-mAbs Therapeutics Stock Performance

Shares of YMAB opened at $13.37 on Tuesday. The firm has a market cap of $595.90 million, a price-to-earnings ratio of -27.29 and a beta of 0.70. Y-mAbs Therapeutics has a fifty-two week low of $4.69 and a fifty-two week high of $20.90. The firm has a 50 day moving average price of $12.50 and a 200-day moving average price of $13.63.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative net margin of 28.44% and a negative return on equity of 24.88%. The firm had revenue of $22.80 million for the quarter, compared to the consensus estimate of $23.09 million. During the same quarter in the prior year, the company earned ($0.14) earnings per share. As a group, equities research analysts predict that Y-mAbs Therapeutics will post -0.57 earnings per share for the current year.

Insider Transactions at Y-mAbs Therapeutics

In other news, COO Joris Wilms sold 5,000 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $14.69, for a total value of $73,450.00. Following the sale, the chief operating officer now directly owns 30,600 shares of the company’s stock, valued at approximately $449,514. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 21.50% of the company’s stock.

Institutional Trading of Y-mAbs Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Ameritas Investment Partners Inc. grew its position in shares of Y-mAbs Therapeutics by 39.9% in the 1st quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock worth $60,000 after buying an additional 1,056 shares during the period. China Universal Asset Management Co. Ltd. grew its position in Y-mAbs Therapeutics by 66.1% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 8,390 shares of the company’s stock valued at $136,000 after purchasing an additional 3,340 shares during the last quarter. Caxton Associates LP purchased a new stake in Y-mAbs Therapeutics during the 1st quarter valued at about $306,000. Price T Rowe Associates Inc. MD grew its position in Y-mAbs Therapeutics by 8.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company’s stock valued at $345,000 after purchasing an additional 1,657 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in Y-mAbs Therapeutics during the 2nd quarter valued at about $297,000. 70.85% of the stock is owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.